| Market Cap | 434M 374M 352M 321M 601M 41.02B 603M 4.16B 1.61B 21.05B 1.63B 1.6B 67.8B | P/E 2026 * |
38.4x | P/E 2027 * | 12.5x |
|---|---|---|---|---|---|
| Enterprise Value | 434M 374M 352M 321M 601M 41.02B 603M 4.16B 1.61B 21.05B 1.63B 1.6B 67.8B | EV / Sales 2026 * |
5.96x | EV / Sales 2027 * | 4.21x |
| Free-Float |
80.61% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Fennec Pharmaceuticals Inc
| 1 day | +1.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeffrey Hackman
CEO | Chief Executive Officer | 64 | 16/08/2024 |
Robert Andrade
DFI | Director of Finance/CFO | 51 | 06/01/2010 |
Pierre Sayad
CTO | Chief Tech/Sci/R&D Officer | 51 | 28/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 72 | 25/08/2011 |
Khalid Islam
CHM | Chairman | 69 | 09/12/2015 |
Marco Brughera
BRD | Director/Board Member | 70 | 10/08/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.29% | +3.66% | - | - | 434M | |
| -0.88% | -2.15% | +54.71% | +106.31% | 1,024B | |
| -1.15% | +2.68% | +53.97% | +71.50% | 663B | |
| -1.44% | +0.38% | +20.40% | +73.05% | 453B | |
| +0.14% | -0.47% | +29.49% | +38.56% | 352B | |
| -1.33% | +4.72% | +24.69% | +45.55% | 304B | |
| -1.15% | +0.30% | -1.49% | +12.31% | 252B | |
| -1.55% | +1.11% | +56.10% | +70.32% | 236B | |
| -0.88% | +1.15% | -17.09% | -54.39% | 206B | |
| -0.15% | +3.65% | +33.90% | +96.99% | 187B | |
| Average | -0.76% | +1.09% | +28.30% | +51.13% | 408.71B | |
| Weighted average by Cap. | -1.10% | +0.55% | +36.62% | +66.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 72.9M 62.73M 59.02M 53.92M 101M 6.88B 101M 697M 271M 3.53B 274M 268M 11.38B | 103M 88.76M 83.51M 76.29M 143M 9.74B 143M 987M 383M 5B 387M 379M 16.1B |
| Net income | 11.25M 9.68M 9.1M 8.32M 15.56M 1.06B 15.6M 108M 41.75M 545M 42.23M 41.31M 1.76B | 35.24M 30.32M 28.53M 26.06M 48.75M 3.33B 48.88M 337M 131M 1.71B 132M 129M 5.5B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
